The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes
Open accessThe DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor (GLP-1R) agonists are a class of newly introduced antidiabetic medications that potentially lower blood glucose by several molecular pathways. DPP-4 inhibitors are the other type of novel antidiabetic medications which act by preventing GLP-1 inactivation and thereby increasing the activity levels of GLP-1, leading to more glucose-induced insulin release from islet β-cells and suppression of glucagon release. Most patients with diabetes have concurrent hypertension and cardiovascular disorder. If antihyperglycemic agents can attenuate the risk of hypertension and cardiovascular disease, they will amplify their overall beneficial effects. There is conflicting evidence on the cardiovascular benefits of GLP-1R induction in laboratory studies and clinical trials. In this study, we have reviewed the main molecular mechanisms by which GLP-1R induction may modulate the cardiovascular function and the results of cardiovascular outcome clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP1-RA also lower blood pressure; the mechanisms underlying this effect are still under investigation[36] but may be partially attributed to the increase in natriuresis [31].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988 · cited 3×
“Type 1 DM (T1DM) accounts for about 5-10% of all patients with diabetes and results from autoimmune destruction of beta-cells of the pancreas and absolute deficiency of insulin [30].”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“NCT01179048 9340 patients with T2DM Liraglutide Reduces the risk of cardiovascular disorders [112]”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“NCT01720446 3297 patients with T2DM Semaglutide Reduces the risk of diabetes-induced cardiovascular problems [116] 5 Journal of Diabetes Research”
BackgroundDiagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Chen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,742
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 2×
“They act as an agonist to GLP-1 receptors and mimic the effects of incretin hormones [14, 15].”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 3×
“These antihyperglycemic agents activate their specific receptor known as GLP-1R, predominantly located in pancreatic βcell [17].”
Background2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159 · cited 2×
“DPP-4 inhibitors are the other type of novel antidiabetic medications which act by preventing GLP-1 inactivation and thereby increasing the activity levels of GLP-1, leading to more glucose-induced insulin release from islet β-cells and suppression of glucagon release [27, 28].”
BackgroundLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“NCT01147250 6068 patients with T2DM Lixisenatide No significant effects on diabetes-induced cardiovascular diseases [114]”
BackgroundEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · cited 1×
“NCT01144338 14752 patients with T2DM Exenatide No significant effects on diabetes-induced cardiovascular diseases [115]”
BackgroundHernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829 · cited 1×
“NCT02465515 9463 patients with T2DM Albiglutide Diminishes the risk of diabetes-induced cardiovascular complications [113]”
BackgroundSelf-citationDiabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I
Creager, M. A., Lüscher, T. F., of, P. W. T. A., Cosentino, F., & Beckman, J. A. (2003) · Circulation · doi:10.1161/01.cir.0000091257.27563.32 · Cited by 1,650
Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012
Mayer-Davis, E. J., Lawrence, J. M., Dabelea, D., Divers, J., Isom, S., Dolan, L., Imperatore, G., Linder, B., Marcovina, S., Pettitt, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1610187 · Cited by 1,476
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
Paneni, F., Beckman, J. A., Creager, M. A., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht149 · Cited by 1,401
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 1×
“NTC00294723 746 patients with early T2DM Liraglutide Potentially reduces blood pressure after 52 weeks [109]”
BackgroundGlomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835 · cited 1×
“NCT00331851 581 patients with T2DM Liraglutide Has no significant effects on systolic blood pressure [110]”
Diabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714 · cited 3×
“Likewise, other prevalent forms of diabetes complications such as diabetic neuropathy and diabetic retinopathy are potentially influenced by molecular pathways induced by hemodynamic changes and systemic hypertension [10, 35, 43, 44].”
BackgroundDomingueti, C. P., Dusse, L. M. S., Carvalho, M. D. G., de Sousa, L. P., Gomes, K. B., & Fernandes, A. P. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.12.018 · Cited by 647 · cited 1×
“Diabetes complications are classified mainly as microvascular and macrovascular complications, both of which are worsened by hemodynamic variations and increased blood pressure (BP) [6, 7].”
BackgroundThe changing face of diabetes complications
Gregg, E. W., Sattar, N., & Ali, M. K. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30010-9 · Cited by 612 · cited 1×
“Nowadays, diabetes complications are a leading cause of disability and mortality, especially in the elderly worldwide [3].”
BackgroundDing, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514 · cited 1×
“In addition to the pathways mentioned above, the other potential mechanisms suggested are ANP release induction [106], natriuresis induction [90, 92, 102, 107], antiinflammatory effects [92], improvement in lipid metabolism, and lower risk for atherosclerosis [108].”
BackgroundComorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection
Long, A. N., & Dagogo‐Jack, S. (2011) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00434.x · Cited by 491 · cited 1×
“Emerging studies have well demonstrated that the simultaneous presence of hypertension is a main upstream event and potent risk factor which can induce or exacerbate the progression of diabetes complications [35, 36].”
BackgroundGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 3×
“Central nervous system Activates the sympathetic nervous system leading to a higher heart rate and blood pressure [66, 85, 86, 88]”
BackgroundYamamoto, H., Lee, C. E., Marcus, J., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L. L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15595 · Cited by 473
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
Minireview: The Glucagon-Like Peptides
Drucker, D. J. (2001) · Endocrinology · doi:10.1210/en.142.2.521 · Cited by 421 · cited 1×
“It has been proposed that GLP-1 enhances glucose disposal in an insulin-independent mechanism [46].”
BackgroundButeau, J., Foisy, S., Joly, E., & Prentki, M. (2003) · Diabetes · doi:10.2337/diabetes.52.1.124 · Cited by 411
Meloni, A. R., DeYoung, M. B., Lowe, C., & Parkes, D. G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01663.x · Cited by 407 · cited 1×
“In the pancreas, it stimulates insulin secretion by many molecular pathways including the release of cyclic adenosine monophosphate (cAMP) by activating βarrestin-1 (βARR1), activates the voltage Ca channels, and induces the Ca influx which raises the intracellular Ca and stimulates the insulin release [47, 48].”
BackgroundGLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407 · cited 2×
“In addition to the pathways mentioned above, the other potential mechanisms suggested are ANP release induction [106], natriuresis induction [90, 92, 102, 107], antiinflammatory effects [92], improvement in lipid metabolism, and lower risk for atherosclerosis [108].”
BackgroundLozano, I., Van der Werf, R., Bietiger, W., Seyfritz, E., Peronet, C., Pinget, M., Jeandidier, N., Maillard, E., Marchioni, E., Sigrist, S., et al. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0074-1 · Cited by 327
Renal Dysfunction Complicating the Treatment of Hypertension
Palmer, B. F. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020676 · Cited by 326 · cited 2×
“Renal dysfunctions accompany many cases of HTN, and improvement in renal function improves the cardiovascular outcome [89].”
BackgroundArterial stiffness in diabetes mellitus
Prenner, S. B., & Chirinos, J. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.023 · Cited by 313
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304
Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does!
Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc14-2898 · Cited by 282 · cited 1×
“This chronic disorder is accompanied by metabolic derangements and activation of various pathophysiologic pathways leading to tissue dysfunction [2].”
BackgroundShiraki, A., Oyama, J.-I., Komoda, H., Asaka, M., Komatsu, A., Sakuma, M., Kodama, K., Sakamoto, Y., Kotooka, N., Hirase, T., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.039 · Cited by 263
Buteau, J., Foisy, S., Rhodes, C. J., Carpenter, L., Biden, T. J., & Prentki, M. (2001) · Diabetes · doi:10.2337/diabetes.50.10.2237 · Cited by 252
Yaribeygi, H., Atkin, S. L., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27164 · Cited by 243
Self-citationHoward, B. V. (2008) · JAMA · doi:10.1001/jama.299.14.1678 · Cited by 241
Hendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., & Takayanagi, R. (2012) · Metabolism · doi:10.1016/j.metabol.2012.03.002 · Cited by 232 · cited 1×
“Some evidence indicated that GLP-1 receptor activation might improve oxidative stress [74].”
BackgroundVascular system: role of nitric oxide in cardiovascular diseases
Bian, K., Doursout, M., & Murad, F. (2008) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.06632.x · Cited by 229 · cited 1×
“Nitric oxide (NO) plays a significant role in vascular homeostasis and the normal physiologic function of the cardiovascular system [79].”
BackgroundSkov, J., Dejgaard, A., Frøkiær, J., Holst, J. J., Jonassen, T., Rittig, S., & Christiansen, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3855 · Cited by 228 · cited 4×
“In addition to the pathways mentioned above, the other potential mechanisms suggested are ANP release induction [106], natriuresis induction [90, 92, 102, 107], antiinflammatory effects [92], improvement in lipid metabolism, and lower risk for atherosclerosis [108].”
BackgroundInfluentialBasu, A., Charkoudian, N., Schrage, W., Rizza, R. A., Basu, R., & Joyner, M. J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00373.2007 · Cited by 226 · cited 8×
“In a study by Basu et al., it was found that GLP-1 stimulated acetylcholineinduced vasodilatation, improved vascular relaxation, reduced diastolic BP, and has direct beneficial effects on endothelial function in patients with T1DM [61].”
BackgroundInfluentialWang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225
Woo, J. S., Kim, W., Ha, S. J., Kim, J. B., Kim, S.-J., Kim, W.-S., Seon, H. J., & Kim, K. S. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301586 · Cited by 223 · cited 2×
“NCT01580514 58 patients with T2DM and cardiac dysfunction Exenatide Diminishes pulmonary capillary wedge pressure and improved coronary blood flow [98]”
BackgroundAhrén, B. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.07.005 · Cited by 204 · cited 1×
“DPP-4 inhibitors are the other type of novel antidiabetic medications which act by preventing GLP-1 inactivation and thereby increasing the activity levels of GLP-1, leading to more glucose-induced insulin release from islet β-cells and suppression of glucagon release [27, 28].”
BackgroundCeriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204 · cited 7×
“Vascular endothelial cells have a significant role in the homeostasis of cardiovascular function and BP homeostasis [58, 59].”
BackgroundInfluentialChai, W., Dong, Z., Wang, N., Wang, W., Tao, L., Cao, W., & Liu, Z. (2012) · Diabetes · doi:10.2337/db11-1073 · Cited by 194
Hypertension with diabetes mellitus complications
Yamazaki, D., Hitomi, H., & Nishiyama, A. (2018) · Hypertension Research · doi:10.1038/s41440-017-0008-y · Cited by 188 · cited 3×
“Many forms of diabetes complications such as diabetic nephropathy, diabetic retinopathy, stroke, and DM-related cardiovascular disorders such as atherosclerosis are closely associated with hemodynamic variations and hypertension [35].”
BackgroundLiu, L., Liu, J., Wong, W. T., Tian, X. Y., Lau, C. W., Wang, Y.-X., Xu, G., Pu, Y., Zhu, Z., Xu, A., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.195115 · Cited by 179 · cited 2×
“Also, Liu and coworkers demonstrated that DPP-4i reduced BP by improving endothelial function in hypertensive rats [62].”
BackgroundLovshin, J. A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., & Drucker, D. J. (2015) · Diabetes Care · doi:10.2337/dc14-1958 · Cited by 168 · cited 1×
“In addition to the pathways mentioned above, the other potential mechanisms suggested are ANP release induction [106], natriuresis induction [90, 92, 102, 107], antiinflammatory effects [92], improvement in lipid metabolism, and lower risk for atherosclerosis [108].”
BackgroundExendin-4 has an anti-hypertensive effect in salt-sensitive mice model
Hirata, K., Kume, S., Araki, S.-I., Sakaguchi, M., Chin-Kanasaki, M., Isshiki, K., Sugimoto, T., Nishiyama, A., Koya, D., Haneda, M., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.003 · Cited by 163 · cited 1×
“Also, Hirata and Kume found that exendin-4 improved renal sufficiency and ameliorated HTN in angiotensin-induced hypertensive rats [93].”
BackgroundAlter, M. L., Ott, I. M., von Websky, K., Tsuprykov, O., Sharkovska, Y., Krause-Relle, K., Raila, J., Henze, A., Klein, T., & Hocher, B. (2012) · Kidney and Blood Pressure Research · doi:10.1159/000341487 · Cited by 151
Ding, L., & Zhang, J. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.149 · Cited by 147 · cited 1×
“Ding and Zhang showed that the GLP-1 agonist induced NO mRNA expression and improved NO synthesis in endothelial cells of the umbilical vein [80].”
BackgroundMarney, A., Kunchakarra, S., Byrne, L., & Brown, N. J. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.156554 · Cited by 147 · cited 5×
“Central nervous system Activates the sympathetic nervous system leading to a higher heart rate and blood pressure [66, 85, 86, 88]”
BackgroundInfluentialLiu, J., Yin, F., Zheng, X., Jing, J., & Hu, Y. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.04.021 · Cited by 145 · cited 1×
“This could be mediated via inhibition of free radical generation by cyclooxygenase 2 and/or NADPH oxidase downregulation of the MAPK (mitogen-activated protein kinase) pathway [58, 59, 75].”
BackgroundThe Underlying Role of Oxidative Stress in Neurodegeneration: A Mechanistic Review
Yaribeygi, H., Panahi, Y., Javadi, B., & Sahebkar, A. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666180425122557 · Cited by 141
Self-citationBergenstal, R. M. (2015) · Diabetes Care · doi:10.2337/dc15-0099 · Cited by 140 · cited 1×
“Hence, various therapeutic guidelines and antidiabetic agents have been developed for normalising blood glucose and preventing diabetes-related complications [4, 5].”
BackgroundCasas, J. M. B., Rodríguez, R. E., Eng, J., & Blázquez, E. (1996) · Regulatory Peptides · doi:10.1016/s0167-0115(96)00113-9 · Cited by 125
The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size
Scott, K. A., & Moran, T. H. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00323.2007 · Cited by 113
Griffioen, K. J., Wan, R., Okun, E., Wang, X., Lovett-Barr, M. R., Li, Y., Mughal, M. R., Mendelowitz, D., & Mattson, M. P. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq271 · Cited by 112 · cited 1×
“On the other hand, most of this evidence relied on the positive chronotropic effect of these drugs on HR and suggested that this may be due to modulating the autonomic nervous system, leading to more sympathetic activity [61, 63, 66, 70].”
BackgroundGuo, C., Huang, T., Chen, A., Chen, X., Wang, L., Shen, F., & Gu, X. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165826 · Cited by 112
The Glucagon‐Like Peptides: Pleiotropic Regulators of Nutrient Homeostasis
BRUBAKER, P. L. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1317.006 · Cited by 111
Back to the future: glomerular hyperfiltration and the diabetic kidney
Tuttle, K. R. (2017) · Diabetes · doi:10.2337/dbi16-0056 · Cited by 108 · cited 1×
“However, glomerular hyperfiltration which is considered a hemodynamic abnormality in kidneys also acts as an independent risk factor for diabetic nephropathy in patients with diabetes [38, 39].”
BackgroundRanjbar, G., Mikhailidis, D. P., & Sahebkar, A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154001 · Cited by 107
Self-citationMetformin Reverses Development of Pulmonary Hypertension via Aromatase Inhibition
Dean, A., Nilsen, M., Loughlin, L., Salt, I. P., & MacLean, M. R. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07353 · Cited by 105
Yang, W., Chen, L., Ji, Q., Liu, X., Ma, J., Tandon, N., Bhattacharyya, A., Kumar, A., Kim, K.-W., Yoon, K., et al. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01323.x · Cited by 97
Wootten, D. L., Simms, J., Koole, C., Woodman, O. L., Summers, R. J., Christopoulos, A., & Sexton, P. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176362 · Cited by 90 · cited 1×
“Its activation is followed by higher production of cAMP (cyclic adenosine monophosphate), cellular depolarisation, and augmentation in intracellular calcium concentration insulin secretion from pancreatic β-cells [17, 26].”
BackgroundMaraschin, J. D. F. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_2 · Cited by 89 · cited 1×
“Gestational diabetes is another type of DM that happens in pregnant women mainly via hormonal variation-induced insulin resistance in pregnancy [31].”
GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress
Jiang, Y., Wang, Z., Ma, B., Fan, L., Yi, N., Lu, B., Wang, Q., & Liu, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01168 · Cited by 88 · cited 1×
“Moreover, GLP-1RAs reduce the stress in the endoplasmic reticulum (ER) by modulating the protein kinase R-like endoplasmic reticulum (PERK) pathway and activate the transcription factor 4 (ATF4) and CHOP (C/EBP homologous protein) [53].”
BackgroundLiu, L., Liu, J., Tian, X. Y., Wong, W. T., Lau, C. W., Xu, A., Xu, G., Ng, C. F., Yao, X., Gao, Y., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5519 · Cited by 86
Alam, M. A., Chowdhury, M. R. H., Jain, P., Sagor, M. A. T., & Reza, H. M. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0095-3 · Cited by 83 · cited 1×
“demonstrated that sitagliptin inhibits oxidative stress in vascular cells and improves arterial function of the kidneys and heart of rats [78].”
BackgroundMason, R. P., Jacob, R. F., Kubant, R., Ciszewski, A., Corbalan, J. J., & Maliñski, T. (2012) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31826be204 · Cited by 81 · cited 2×
“We have similar evidence concerning DPP-4i and NO synthesis [83].”
BackgroundMethodLee, M.-Y., Tsai, K.-B., Hsu, J.-H., Shin, S.-J., Wu, J.-R., & Yeh, J.-L. (2016) · Scientific Reports · doi:10.1038/srep31788 · Cited by 80 · cited 2×
“Lee and colleagues found that liraglutide reduces PAP via eNOS/sGC/PKG and rho kinase pathways in diabetic rats (soluble guanylyl cyclase (sGC), protein kinase G (PKG)) [97].”
BackgroundNakatani, Y., Kawabe, A., Matsumura, M., Aso, Y., Yasu, T., Banba, N., & Nakamoto, T. (2016) · Diabetes Care · doi:10.2337/dc15-1437 · Cited by 77 · cited 11×
“Type 2 DM (T2DM) (NIDDM) is the most prevalent form of DM, which accounts for about 90-95% of diabetic subjects and is mainly associated with various pathologies, including insulin resistance and beta-cell dysfunction [30].”
BackgroundInfluentialRecognizing and Appropriately Treating Latent Autoimmune Diabetes in Adults
O’Neal, K. S., Johnson, J. L., & Panak, R. L. (2016) · Diabetes Spectrum · doi:10.2337/ds15-0047 · Cited by 76
Yaribeygi, H., Atkin, S. L., Pirro, M., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27699 · Cited by 72 · cited 2×
“GLP-1RA is a class of newly introduced antidiabetic medications that are FDA approved in 2010 to manage patients with diabetes [9].”
BackgroundSelf-citationDong, Z., Chai, W., Wang, W., Zhao, L., Fu, Z., Cao, W., & Liu, Z. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00473.2012 · Cited by 71 · cited 2×
“Moreover, Dong and colleagues reported that GLP-1 acutely stimulated eNOS phosphorylation at Ser(1177) and NO production by a PKAdependent pathway, leading to improved microvascular muscle blood flow [82].”
BackgroundKoren, S., Shemesh-Bar, L., Tirosh, A., Peleg, R. K., Berman, S., Hamad, R. A., Vinker, S., Golik, A., & Efrati, S. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0296 · Cited by 69 · cited 7×
“However, there is only minimal direct evidence about the effects of GLP-1 on oxidative stress-induced HTN [77].”
BackgroundInfluentialNeuromodulatory effects of anti-diabetes medications: A mechanistic review
Yaribeygi, H., Ashrafizadeh, M., Henney, N. C., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104611 · Cited by 69
Self-citationLiu, Q., Adams, L., Broyde, A., Fernandez, R., Baron, A. D., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-32 · Cited by 66
Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2019.117152 · Cited by 63
Self-citationMcClenaghan, N. H. (2007) · Experimental Physiology · doi:10.1113/expphysiol.2006.034835 · Cited by 61
Farr, S., Taher, J., & Adeli, K. (2014) · Cardiovascular & Hematological Disorders-Drug Targets · doi:10.2174/1871529x14666140505125300 · Cited by 61 · cited 1×
“In addition to the pathways mentioned above, the other potential mechanisms suggested are ANP release induction [106], natriuresis induction [90, 92, 102, 107], antiinflammatory effects [92], improvement in lipid metabolism, and lower risk for atherosclerosis [108].”
BackgroundRole of Insulin-Mediated Antinatriuresis in Sodium Homeostasis and Hypertension
Brands, M. W. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11728 · Cited by 55
Gardiner, S. M., March, J. E., Kemp, P. A., & Bennett, T. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093104 · Cited by 51 · cited 2×
“Central nervous system (CNS) activity, especially the autonomic nervous system (ANS), has a prominent role in cardiovascular function and control of BP [67].”
BackgroundRomacho, T., Vallejo, S., Villalobos, L. A., Wronkowitz, N., Indrakusuma, I., Sell, H., Eckel, J., Sánchez‐Ferrer, C. F., & Peiró, C. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000886 · Cited by 51 · cited 1×
“reported that DPP-4i improves endothelial function by activation of PAR2 (protease-activated receptor 2) and release of thromboxaneA2 in mice [64], Nomoto et al.”
BackgroundmiR-7 Regulates GLP-1-Mediated Insulin Release by Targeting β-Arrestin 1
Matarese, A., Gambardella, J., Lombardi, A., Wang, X., & Santulli, G. (2020) · Cells · doi:10.3390/cells9071621 · Cited by 45
Al-Awar, A., Almási, N., Szabó, R., Takács, I., Murlasits, Z., Szűcs, G., Török, S., Pósa, A., Varga, C., & Kupai, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103226 · Cited by 44 · cited 2×
“Also, Al-Awar and coworkers reported that sitagliptin, one of the DPP-4is, improved vascular function and reduced BP by NO-dependent molecular mechanisms in rats [84].”
BackgroundLiakos, C. I., Papadopoulos, D. P., Sanidas, E. A., Markou, M. I., Hatziagelaki, E. E., Grassos, C. A., Velliou, M. L., & Barbetseas, J. D. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00423-z · Cited by 43
GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side
Dieter, B. P., Alicic, R. Z., & Tuttle, K. R. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00211.2018 · Cited by 38 · cited 2×
“In addition to the pathways mentioned above, the other potential mechanisms suggested are ANP release induction [106], natriuresis induction [90, 92, 102, 107], antiinflammatory effects [92], improvement in lipid metabolism, and lower risk for atherosclerosis [108].”
BackgroundIncretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37 · cited 1×
“In the pancreas, it stimulates insulin secretion by many molecular pathways including the release of cyclic adenosine monophosphate (cAMP) by activating βarrestin-1 (βARR1), activates the voltage Ca channels, and induces the Ca influx which raises the intracellular Ca and stimulates the insulin release [47, 48].”
BackgroundKuniss, N., Freyer, M., Müller, N., Kielstein, V., & Müller, U. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1217-9 · Cited by 34 · cited 1×
“Hence, various therapeutic guidelines and antidiabetic agents have been developed for normalising blood glucose and preventing diabetes-related complications [4, 5].”
BackgroundA Review on the Effects of New Anti-Diabetic Drugs on Platelet Function
Yaribeygi, H., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666191014110414 · Cited by 34
Self-citationGLP-1R Agonists and Endothelial Dysfunction: More Than Just Glucose Lowering?
Lovshin, J. A., & Cherney, D. Z. I. (2015) · Diabetes · doi:10.2337/db15-0366 · Cited by 32 · cited 1×
“GLP-1 agonists may improve vascular endothelial function in the diabetic milieu [58, 60, 61].”
BackgroundHubers, S. A., Wilson, J. R., Yu, C., Nian, H., Grouzmann, E., Eugster, P. J., Shibao, C. A., Billings, F. T., Kerman, S. R. J., & Brown, N. J. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11498 · Cited by 31 · cited 10×
“Type 2 DM (T2DM) (NIDDM) is the most prevalent form of DM, which accounts for about 90-95% of diabetic subjects and is mainly associated with various pathologies, including insulin resistance and beta-cell dysfunction [30].”
BackgroundResultInfluentialWidlansky, M. E., Puppala, V. K., Suboc, T. M. B., Malik, M. A., Branum, A., Signorelli, K., Wang, J., Ying, R., Tanner, M. J., & Tyagi, S. (2017) · Vascular Medicine · doi:10.1177/1358863x16681486 · Cited by 30 · cited 11×
“demonstrated that DPP-4i has no significant acute effect on endothelial dysfunction in patients with T2DM [63].”
BackgroundInfluentialFan, S.-H., Xiong, Q.-F., Wang, L., Zhang, L.-H., & Shi, Y.-W. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111005 · Cited by 30 · cited 1×
“There is growing evidence that GLP-1 A reverses the vascular remodelling by downregulating the matrix metalloproteinase 1 (MMP1), extracellular-regulated protein kinase 1/2 (ERK1/2), and nuclear factor kappa-β (NF-Kβ) [54].”
BackgroundProtective Effects of Glucagon-like Peptide 1 on Endothelial Function in Hypertension
Liu, L., Liu, J., & Huang, Y. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000176 · Cited by 29 · cited 5×
“Vascular endothelial cells have a significant role in the homeostasis of cardiovascular function and BP homeostasis [58, 59].”
BackgroundInfluentialCosenso‐Martin, L. N., Giollo-Júnior, L. T., Fernandes, L. A. B., Cesarino, C. B., Nakazone, M. A., Machado, M. D. N., Yugar‐Toledo, J. C., & Vilela-Martin, J. F. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1204-1 · Cited by 29
Effects of glucagon‐like peptide‐1 and sympathetic stimulation on gastric accommodation in humans1
Andrews, C. N., Bharucha, A. E., Camilleri, M., Low, P. A., Seide, B. M., Burton, D. D., Nickander, K. K., Baxter, K. L., & Zinsmeister, A. R. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.00923.x · Cited by 26
Antioxidative Potentials of Incretin‐Based Medications: A Review of Molecular Mechanisms
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9959320 · Cited by 26
Self-citationBoye, K. S., Botros, F. T., Haupt, A., Woodward, B., & Lage, M. J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0377-5 · Cited by 23 · cited 1×
“reported that GLP-1R induction was accompanied by a slower deterioration in eGFR (estimated glomerular filtration rate) than that of other antihyperglycemic agents [91].”
ResultRaina, S., Chander, V., Raina, S., Kumar, D., Grover, A., & Bhardwaj, A. K. (2015) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.151045 · Cited by 15 · cited 1×
“Moreover, it is well established that hypertension coexists in a significant proportion of patients with diabetes [8, 9].”
BackgroundYaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117916 · Cited by 15
Self-citationLe, Y., Zheng, Z., Xue, J., Cheng, M., Guan, M., & Xue, Y. (2016) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320316677918 · Cited by 13 · cited 1×
“demonstrated that GLP-1R activation by exendin-4 declined intrarenal RAS activity, leading to a lower Ang IImediated TGF-β1/Smad3 signalling pathway in mice (transforming growth factor-beta (TGF-β1), SMAD family member 3 (Smad3)) [103].”
BackgroundCooper, M. E., Perkovic, V., Groop, P., Hocher, B., Hehnke, U., Meinicke, T. W., Koitka‐Weber, A., van der Walt, S., & von Eynatten, M. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000002032 · Cited by 11 · cited 1×
“suggested that concomitant use of ACE (angiotensin-converting enzyme) inhibitors and DPP-4i potentiates their effect on RAS activity [105].”
BackgroundInsulinotropic Effect of Herbal Drugs for Management of Diabetes Mellitus: A Congregational Approach
Islam, M. N. (2016) · Biosensors Journal · doi:10.4172/2090-4967.1000142 · Cited by 9 · cited 1×
“They act as an agonist to GLP-1 receptors and mimic the effects of incretin hormones [14, 15].”
BackgroundHemodynamic Considerations in the Pathophysiology of Peripheral Neuropathy
Smith, D. I., Tran, H. T., & Poku, J. W. (2018) · InTech eBooks · doi:10.5772/intechopen.75872 · Cited by 6 · cited 1×
“Likewise, other prevalent forms of diabetes complications such as diabetic neuropathy and diabetic retinopathy are potentially influenced by molecular pathways induced by hemodynamic changes and systemic hypertension [10, 35, 43, 44].”
BackgroundBernabéu, M. O., Lu, Y., Lammer, J., Aiello, L. P., Coveney, P. V., & Sun, J. K. (2015) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2015.7320266 · Cited by 4 · cited 1×
“Likewise, other prevalent forms of diabetes complications such as diabetic neuropathy and diabetic retinopathy are potentially influenced by molecular pathways induced by hemodynamic changes and systemic hypertension [10, 35, 43, 44].”
BackgroundPirozzi, F. F. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s13-013 · Cited by 4 · cited 2×
“NCT01755572 22 hypertensive subjects with T2DM Liraglutide While inducing natriuresis, it had no significant effects on blood pressure [99]”
BackgroundThe role of haemodynamic and metabolic factors in the development of diabetic nephropathy
Grzeszczak, W., Wystrychowski, G., & Franek, E. (2013) · Postępy Nauk Medycznych · Cited by 2
Insulinotropic Actions of GLP-1: How Much in the Brain and How Much in the Periphery?
Tudurí, E., & Nogueiras, R. (2017) · Endocrinology · doi:10.1210/en.2017-00410 · Cited by 2 · cited 2×
“Central nervous system Activates the sympathetic nervous system leading to a higher heart rate and blood pressure [66, 85, 86, 88]”
BackgroundDo DPP-4 inhibitors improve endothelial cell function?
Nomoto, H., Miyoshi, H., Nakamura, A., Atsumi, T., Manda, N., Kurihara, Y., & Aoki, S. (2017) · doi:10.35841/cardiology.1.1.12-14 · Cited by 1 · cited 1×
“provided evidence indicating that DPP-4i does not improve endothelial dysfunction [65], suggesting that more evidence is needed to show beneficial effects of these agents on endothelial function.”
BackgroundThe Glucagon-Like Peptide-1 Receptor Agonist Inhibits Hypoxia-Induced Pulmonary Hypertension in Mice
Honda, J., Kimura, T., Sakai, S., Maruyama, H., Homma, S., Miyauchi, T., & Aonuma, K. (2017) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2017.08.347 · Cited by 1
Effect of alogliptin on hypertensive chronic kidney disease patients with type 2 diabetes mellitus
Said, A. S. A., Hussain, N., Haddad, A. H. I. A., & Javid, F. A. (2018) · Australasian Medical Journal · doi:10.21767/amj.2018.3319 · Cited by 1 · cited 7×
“— 76 patients with T2DM Alogliptin Reduced BP by improving renal sufficiency [95]”
BackgroundInfluential
Research works printed but not linked: 2
- 10.1210/endo.142.2.7983 · doi:10.1210/endo.142.2.7983 · Paper page
- S. Hosokawa, 2014, The synergistic effects of incretin-related drugs for the treatment of pulmonary arterial hypertension, American Heart Association, 130, article A13535
Cited by
Michos, E. D., Bakris, G. L., Rodbard, H. W., & Tuttle, K. R. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100502 · Cited by 125
“GLP1-RA also lower blood pressure; the mechanisms underlying this effect are still under investigation[36] but may be partially attributed to the increase in natriuresis [31].”
BackgroundCooper, D. H., Ramachandra, R., Ceban, F., Di Vincenzo, J. D., Rhee, T. G., Mansur, R. B., Teopiz, K. M., Gill, H., Ho, R., Cao, B., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.05.041 · Cited by 79
Rezaei, S., Tabrizi, R., Nowrouzi-Sohrabi, P., Jalali, M., Atkin, S. L., Al-Rasadi, K., Jamialahmadi, T., & Sahebkar, A. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/8936865 · Cited by 65
Self-citationNajafi, S., Bahrami, M., Butler, A. E., & Sahebkar, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15344 · Cited by 39
Self-citationRecent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease
Andreadi, A., Muscoli, S., Tajmir, R., Meloni, M., Muscoli, C., Ilari, S., Mollace, V., Della‐Morte, D., Bellia, A., Daniele, N. D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021646 · Cited by 39
Metadata
- Authors
- Yaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A.
- Affiliations
- Semnan University of Medical Sciences (IR)
- Shahid Beheshti University (IR)
- University of Hull (GB)
- Medical University of Lodz (PL)
- Mashhad University of Medical Sciences (IR)
- Corresponding author
- Yaribeygi, Habib
- Sahebkar, Amirhossein
- ORCID
- Venue
- Journal of Diabetes Research
- Publisher
- Wiley
- Published
- 2021-06-30
- Volume
- 2021
- Pages
- 1-10
- ISSN
- 2314-6745 (ISSN-L)
- 2314-6753
- PMC
- PMC8263148
- OpenAlex
- W3175947914
- Cited by
- 31
- References
- 118
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 4 · 2023: 8 · 2022: 2 · 2021: 1
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Diabetes Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository@Hull (Worktribe) (University of Hull) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Baqiyatallah Hospital
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, DPP-4 inhibitors, blood pressure, hypertension, cardiovascular complications, diabetes mellitus, antidiabetic drugs, cardiovascular outcome trials, glucagon-like peptide-1, insulin secretion, glucagon suppression, antihypertensive effect
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Autonomic Nervous System, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Endothelium, Vascular, Heart Rate, Humans, Hypertension, Hypoglycemic Agents, Nitric Oxide, Renin-Angiotensin System, Comorbidity, Treatment Outcome, Oxidative Stress, Diabetes Complications, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
